[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].
Nephrotic syndrome, uremia, hemodialysis, peritoneal dialysis, and renal transplantation are accompanied by alterations in lipoprotein metabolism In nephrotic patients, total cholesterol, LDL, VLDL and triglycerides are elevated, while HDL may be increased, normal, or decreased. The pathophysiology includes increased hepatic synthesis of VLDL and cholesterol, decreased activity of lipoprotein lipase, and increased urinary excretion of HDL. The risk of coronary heart disease (CHD) is increased in nephrotic patients and elevated LDL-cholesterol may contribute to this risk. Cholesterol lowering diet and drugs are indicated. Presently, Lovastatin and Simvastatin are the most potent cholesterol lowering drugs in nephrotic patients with good evidence of long-term safety. Most patients with impaired renal function or on hemodialysis have moderate hypertriglyceridemia due to decreased lipoprotein lipase activity. HDL may be slightly decreased. Although the risk of CHD is increased in these patients, triglyceride lowering drugs are not indicated, since no benefit can be expected. Peritoneal dialysis is accompanied by elevated VLDL in addition to hypertriglyceridemia. Reabsorption of large amounts of glucose from peritoneal dialysis fluid increases the carbohydrate load and stimulates hepatic VLDL synthesis. Cholesterol lowering therapy may be advantageous, but the experience is very limited. Side effects of lipid lowering drugs may be aggravated in renal failure. Total cholesterol, LDL, VLDL, and triglycerides are elevated in 50% of patients following renal transplantation. Corticosteroids and cyclosporin are major causes of hyperlipidemia. Cholesterol lowering therapy is indicated since the incidence of CHD is increased.(ABSTRACT TRUNCATED AT 250 WORDS)
Olbricht
C J
CJ
Abteilung Nephrologie, Medizinische Hochschule Hannover.
D006801:Humans; D006937:Hypercholesterolemia / Q000378:metabolism; D015228:Hypertriglyceridemia / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007674:Kidney Diseases / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism; D016030:Kidney Transplantation; D008074:Lipoproteins / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D009404:Nephrotic Syndrome / Q000378:metabolism; D014511:Uremia / Q000378:metabolism
D000960:Hypolipidemic Agents; D008074:Lipoproteins
Pathophysiologie und Therapie von Lipidstoffwechselstörungen bei Nierenerkrankungen.